Target intelligence / Profile preview

N-methyl-D-aspartate receptor subunit GluN2A (GluN2A)

Target
GluN2A
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor (specifically, excitatory glutamate receptor family)
01

Overview

N-methyl-D-aspartate receptor subunit GluN2A is a protein encoded by the GRIN2A gene and serves as a regulatory subunit in NMDA receptors, a subclass of glutamate-gated ion channels highly permeable to calcium ions. NMDA receptors are heterotetramers typically formed by two GluN1 and two GluN2A–D subunits, with GluN2A contributing unique channel gating properties, high calcium permeability, and synaptic localization, especially in adult neurons. GluN2A-containing NMDA receptors are crucial for learning, memory, and synaptic plasticity, and disproportionately expressed at synaptic sites due to their interactions with scaffold proteins like PSD-95. Pathological changes in GluN2A function or localization are involved in neurodegenerative and neurodevelopmental diseases. Selective targeting of NMDA receptors containing GluN2A subunits represents a promising therapeutic strategy for neuroprotection and cognitive modulation, but with considerable safety concerns due to the importance of this receptor in normal brain function[1][2][3][8].

Other names
GRIN2A (gene name)Glutamate [NMDA] receptor subunit epsilon-1NMDA receptor subunit 2ANMDAR subunit GluN2A
02

Mechanism of action

Noncompetitive inhibition (memantine, ketamine block channel pore); Competitive antagonism at the glutamate site (not commonly used clinically, but utilized in experiments); Allosteric modulation (zinc restricts activity; experimental selective antagonists act via allosteric sites)

03

Biological functions

Signal transduction (mediates excitatory neurotransmission in CNS)Learning and memory (involved in synaptic plasticity)Cell death and neuroprotection (contributes to both physiological and pathological processes)
04

Disease associations

Neurodegenerative disease (e.g., implicated in Alzheimer's, Parkinson’s disease)EpilepsyCognitive disordersNeurodevelopmental disorders
05

Safety considerations

Risk of excitotoxicity if NMDA signaling is overactivePotential cognitive impairment with excessive NMDA antagonismNarrow therapeutic window for NMDAR-modulating drugs
06

Interacting drugs

Memantine

4 more in the full profile.

07

Biomarkers

Expression levels and mutations in GRIN2A (gene mutations linked to epilepsy and cognitive disorders)Changes in synaptic localization/ratio of GluN2A to GluN2B subunits (biomarker for neurodevelopmental and neurodegenerative conditions)

Beyond the preview

Go deeper on N-methyl-D-aspartate receptor subunit GluN2A (GluN2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-methyl-D-aspartate receptor subunit GluN2A (GluN2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call